Cost-effectiveness of a Population-based AAA Screening Program for Men Over 65 Years Old in Iran

Rajabali Daroudi  
Tehran University of Medical Sciences

Omid Shafe  
Rajaie Cardiovascular Medical and Research Center

Jamal Moosavi  
Rajaie Cardiovascular Medical and Research Center

Javad Salimi  
Tehran University of Medical Sciences

Yahya Bayazidi  
Tehran University of Medical Sciences

Mohammad Reza Zafarghandi  
Rajaie Cardiovascular Medical and Research Center

Majid Maleki  
Rajaie Cardiovascular Medical and Research Center

Majid Moini  
Tehran University of Medical Sciences

Pezhman Farshidmehr  
Tehran University of Medical Sciences

Parham Sadeghipour  
Rajaie Cardiovascular Medical and Research Center  
https://orcid.org/0000-0001-9602-0513

Research

Keywords: Abdominal aortic aneurysm, Cost-effectiveness, Screening, open surgical repair, endovascular aneurysm repair

DOI: https://doi.org/10.21203/rs.3.rs-40160/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background: Screening program tend to recognized patients in their early stage and consequently improve health outcomes. Cost-effectiveness of the abdominal aortic aneurysm (AAA) screening program has been scarcely studied in developing countries. We sought to evaluate the cost-effectiveness of a screening program for the abdominal aortic aneurysm (AAA) in men aged over 65 years in Iran.

Methods: A Markov cohort model with 11 mutually exclusive health statuses was used to evaluate the cost-effectiveness of a population-based AAA screening program compared with a no-screening strategy. Transitions between the health statuses were simulated by using 3-month cycles. Data for disease transition probabilities and quality of life outcomes were obtained from published literature, and costs were calculated based on the price of medical services in Iran and the examination of the patients’ medical records. The outcomes were life-years gained, the quality-adjusted life-year (QALY), costs, and the incremental cost-effectiveness ratio (ICER). The analysis was conducted for a lifetime horizon from the payer’s perspective. Costs and effects were discounted at an annual rate of 3%. Uncertainty surrounding the model inputs was tested with deterministic and probabilistic sensitivity analyses.

Results: The mean incremental cost of the AAA screening strategy compared with the no-screening strategy was $140 and the mean incremental QALY gain was 0.025 QALY, resulting in an ICER of $5566 per QALY gained. At a willingness-to-pay of 1 gross domestic product (GDP) per capita ($5628) per QALY gained, the probability of the cost-effectiveness of AAA screening was about 50%. However, at a willingness-to-pay of twice the GDP per capita per QALY gained, there was about a 95% probability for the AAA screening program to be cost-effective in Iran.

Conclusions: The results of this study showed that at a willingness-to-pay of 1 GDP per capita per QALY gained, a 1-time AAA screening program for men aged over 65 years could not be cost-effective. Nevertheless, at a willingness-to-pay of twice the GDP per capita per QALY gained, the AAA screening program could be cost-effective in Iran. Further, AAA screening in high-risk groups could be cost-effective at a willingness-to-pay of 1 GDP per capita per QALY gained.

Background

An aneurysm is characterized as a pathological, permanent dilation of a vessel [1]. The main agreed-upon definition of the problem is based on the diameter size of the vessel. For an abdominal aortic aneurysm (AAA), a diameter size of greater than 3 cm, with an increased risk for rupture, is accepted as an aneurysm [2].

Investigations in the United States, United Kingdom, Sweden, and Australia have indicated that AAA may affect 1.6% to 7.2% of the population older than 50 years. Also in terms of prevalence, AAA is 4 to 15 times more common in men than in women and its incidence rises in tandem with age [3-6].

Approximately 200 000 cases with AAA are diagnosed annually in the United States, with nearly 15 000 cases of this total at high risk of rupture. The aortic rupture is often fatal, and between 59% and 83% of these patients expire before admission to the hospital. After acute rupture, the mortality rate of emergent surgery is more than 40%. Indeed, only between 10% and 25% of cases with aortic rupture are likely to survive until discharge time [7-9].
The risk of rupture is related to the size of the aneurysm. In other words, an increase in the size of the dilation is concomitant with an increase in the chance of rupture. The risk of aortic rupture in women is 4 times that in men and twice as high in smokers as in nonsmokers [10, 11].

There is currently a dearth of data on the global economic burden and total cost of AAA; however, the average hospitalization time and the cumulative cost of unruptured and ruptured aneurysms are, respectively, 6.7 and 10.7 days and $59,000 and $93,000 [12].

Open surgical repair (OSR) and endovascular aneurysm repair (EVAR) are 2 accepted treatment modalities for AAA. Research shows that the short-term morbidity rate in EVAR is lower than that in OSR; still, it appears that EVAR increases the risk of reoperation and long-term mortality [13-16]. Such findings denote the usefulness of screening methods for the early diagnosis of AAA, especially in light of the fact that not only are most patients with AAA asymptomatic and complications increase the mortality rate but also therapeutic interventions are expensive. The most common screening strategies for the early detection of AAA are ultrasound sonography and computed tomography angiography (CTA). Aortic sizing is reportedly more accurate on CTA, at the expense of radiation exposure and the risk of contrast-induced kidney injury. Ultrasound sonography is now deemed the gold standard for AAA screening on the strength of its accessibility, generalizability, and safety [17-19].

In the early years of the current century, several randomized clinical trials showed that ultrasound screening for AAA had a significant effect on reducing its mortality [20-22]. Similarly, several economic evaluation studies in Western countries have reported that AAA screening in men over 65 years old is highly cost-effective [23-27]. Such results have prompted some medical societies such as the European Society for Vascular Surgery and the United States Preventive Services Taskforce to recommend AAA screening [28, 29], paving the way for the implementation of nationwide AAA screening programs in several Western countries [30].

Research in Asia is hampered by the current paucity of information about the prevalence of AAA. Be that as it may, the available data indicate that the prevalence of the disease in Asian countries is lower than that in European and American countries [31-33]. Accordingly, given the uncertainty as to the cost-effectiveness of AAA screening in Asian countries, we aimed to evaluate the cost-effectiveness of a 1-time screening program for AAA in men aged over 65 years in Iran.

**Methods**

**Model Structure**

In the present study, a previously published Markov model [34, 35] was employed to evaluate the long-term costs and clinical outcomes of the screening strategy in comparison with the no-screening strategy (Fig. 1). The Markov model considers 11 mutually exclusive health statuses to simulate AAA progression. The health statuses in the model are as follows: no AAA, 6 AAA statuses (3 undetected AAAs and 3 detected AAAs), 2 postoperative statuses (post-EVAR and post-OSR), death from AAA, and death from other causes. Each of the 3 AAA statuses represents different sizes of aneurysms: small (3–4.4 cm), medium (4.4–5.4 cm), and large (> 5.5 cm). Each arrow in Figure 1 characterizes a possible transition. Undetected AAAs may be detected by screening or opportunistically. If an aneurysm is detected, ultrasound monitoring is conducted annually for small AAAs and every 6 months for medium AAAs. Patients with aneurysms greater than 5.5 cm undergo elective repair.
surgery. Rupture may occur in all detected and undetected AAAs. Rupture is followed by 2 scenarios: either patients may die and transit to the status of death from AAA or they may undergo an emergency repair surgery. OSR and EVAR are the suggested surgical interventions for both elective and emergency repair operations. The main complications of surgical methods are myocardial infarction, stroke, renal failure, and death. After surgery, patients may transit to one of the 2 postoperative statuses depending on the type of surgery or die and transit to the status of death from AAA. In all living statuses, patients may die due to other causes and transit to the status of death from other causes.

Model Parameters

The parameters of the Markov model utilized in the current investigation are depicted in Table 1. The prevalence of AAA was extracted from a previous study in Iran and studies in other countries [36-38]. On the assumption that the size distribution of aneurysms in Iran was similar to that in the United Kingdom, the value at the initial cycle was obtained from an AAA screening program run by that country’s National Health System [34]. The probabilities of transition between the AAA statuses and the probabilities of rupture in the different AAA statuses were extracted from a systematic review study [39] and an economic evaluation study conducted in the United Kingdom [34]. The proportion of each surgical type in Iran was obtained by an expert panel. Further, the probability of death after emergency and elective surgery was extracted from previous studies conducted in Iran and other countries [34, 35, 40-42]. The probabilities of reoperation after EVAR and OSR and health-related quality of life for men of different ages were extracted from a study by Zarrouk et al [35]. Disutility due to surgery was obtained from an investigation by Lederle et al [43]. Age-specific all-cause mortality rates for the Iranian population were obtained from the available Iranian life tables [44].

The cost for the screening and follow-up of a patient with a detected small or large AAA was calculated based on the price of physician visits and ultrasound examinations in Iran in 2017. The costs of EVAR and OSR were estimated by examining the medical records of 110 hospitalized patients in 2 referral hospitals in Iran (Rajaie Cardiovascular Medical and Research Center and Sina Hospital). Only direct medical costs were calculated; these costs encompassed those of all diagnostic and treatment modalities—namely hospitalization, laboratory, imaging, physician visit, surgery, complications, and treatment. All costs were converted to US dollars according to the then official exchange rate, which was $1 = 34 212 IR Rials in 2017 [45].

Analysis

Two identical cohorts of men aged 65 years old were simulated. The first cohort was invited to be screened with ultrasound sonography, but the second cohort was not invited. The model applied a 3-month cycle length for a lifetime horizon. All future costs and effects were discounted at a 3% annual rate. A half-cycle correction was used for both costs and effects on the assumption that both costs and effects occur halfway through a model cycle. The outcomes were life-years gained, the quality-adjusted life-year (QALY), and costs. The analysis was carried out for a lifetime horizon from the point of view of the payer. Additionally, the incremental cost-effectiveness ratio (ICER) was calculated to compare the 2 strategies of screening and no screening. The TreeAge Pro software (TreeAge Pro Software, Inc, Williamston, MA) was utilized for data modeling.

Sensitivity Analysis
Deterministic and probabilistic sensitivity analyses were undertaken to allow for parameter uncertainty. The range used for the uncertainty around the point estimate of each variable and the distribution used in the probabilistic sensitivity analysis are presented in Table 1.

Results

Base-Case Analysis

The main results from the base-case analysis are shown in Table 2. The mean incremental cost of the AAA screening strategy compared with the no-screening strategy was $140 and the mean incremental QALY gain was 0.025 QALY, resulting in an ICER of $5566 per QALY gained. The incremental health gain in terms of life-year was 0.034, yielding an ICER of $4106 per life-year gained.

Sensitivity Analysis

Most of the parameters in the 1-way sensitivity analysis had a limited effect on the results. The variables that influenced the model outcomes the most were the discount rate, the cost of EVAR, the probability of rupture in undetected large AAAs, the cost of screening tests, and the prevalence of AAA. The results of the 1-way sensitivity analysis for the selected variables are presented in Table 3. At a 6% discount rate on health gains and costs, the ICER changed to about $7334 per QALY gained. (The undiscounted equivalent was about $4151 per QALY gained). When the cost of EVAR was increased to $20 722, the ICER rose to $8409 per QALY gained, while decreasing the cost of EVAR to $8289 diminished the ICER to $4144 per QALY gained. A change in the probability of the rupture of undetected large AAAs between the lower and upper limits led to a variation of the ICER of between $7524 and $4618 per QALY gained. Moreover, an increase or a decrease in the cost of screening tests by about 40% resulted in a variation of the ICER of between $5153 and $6103 per QALY gained. Finally, when the prevalence of AAA was reduced to 1%, the ICER rose to $7890 per QALY gained; and when the prevalence was increased to 4%, the ICER dropped to $5275 per QALY gained.

Probabilistic Sensitivity Analysis

The cost-effectiveness acceptability curve at different thresholds of willingness to pay (Fig. 2) shows that the probability of the cost-effectiveness of AAA screening was 0.5 at a threshold of $6000 per QALY gained and 0.95 at a threshold of $12 000 per QALY gained.

Discussion

In this study, we investigated the cost-effectiveness of a 1-time AAA screening program for men aged over 65 years in Iran. Our analysis showed that at a willingness-to-pay of 1 gross domestic product (GDP) per capita ($5628) per QALY gained, the probability of the cost-effectiveness of AAA screening was about 50%; while at a willingness-to-pay of twice the GDP per capita per QALY gained, there was approximately a 95% probability for the AAA screening program to be cost-effective in Iran. To the best of our knowledge, the present study is the only investigation to analyze the cost-effectiveness of an AAA screening program in a developing country.

Our sensitivity analysis revealed that our results were sensitive to the prevalence of AAA. Based on our 1-way sensitivity analysis results, AAA screening could be cost-effective at a threshold of 1 GDP per capita ($5628) per
QALY gained, if the prevalence of AAA in Iran was 4% or greater. Furthermore, AAA screening could be cost-effective at a threshold of twice the GDP per capita per QALY gained, if the prevalence of AAA in Iran was 1% or greater.

Recent years have witnessed a change in the epidemiology of AAA in Western countries, the most striking of which is the significantly reduced prevalence rate of AAA owing to alterations in smoking habits, followed by the improved management of cardiovascular risk factors [33, 46]. Although these epidemiological changes have raised questions over the cost-effectiveness of AAA screening, the results of recent economic evaluation studies in Western countries have demonstrated that AAA screening in men aged 65 years or above is still cost-effective in the new context [34, 35, 42, 47, 48]. There is, however, no evidence of a decrease in the prevalence of AAA in Asian countries, including Iran [31, 38]. Our extensive literature search showed only a few studies on the prevalence of AAA in Iran [37, 49, 50]. The salient point as regards these investigations is that their focus on special patient groups greatly lessens the applicability of their results to the general population of Iran.

Mirsharifi et al [37] reported a prevalence rate of 10% for AAA in men older than 65 years from among patients who referred for ultrasound sonography to 3 different centers in Tehran, Iran, in the year 2008. Shirani et al [50] found a prevalence rate of 3.8% for AAA in men aged over 65 years from among the candidates for coronary artery bypass graft surgery in Tehran Heart Center. Recent reports on the prevalence of AAA in Europe in the last decade have shown a clear decline significantly related to successful strategies for risk factor modification [35, 51]. In contrast, the current status of the strategies aimed at modifying AAA risk factors in developing countries would logically hint at a higher rate of AAA incidence. Assuming a comparable status concerning the prevalence of AAA in the general populations of men aged 65 years or above in Europe and Iran, we can conclude that AAA screening could not be cost-effective. Still, the fact that local studies indicate relatively high rates of AAA in high-risk groups would bolster the argument in favor of screening such patients.

More recently, the results of a systematic review study commissioned by the United States Preventive Services Task Force showed that 1-time AAA screening in men 65 years or older was associated with decreased AAA-related mortality and rupture rates and increased rates of elective surgery, but it was not associated with all-cause mortality benefits and long-term differences in the quality of life resulting from screening [52]. Based on these findings, the said task force recommended 1-time screening for AAA with ultrasonography in men aged 65 to 75 years who have ever smoked and selective screening for AAA with ultrasonography in men aged 65 to 75 years who have never smoked rather than routinely screening all men in this group [53].

The cost of EVAR was another variable that greatly influenced the results of our model. Based on expert opinion in this study, EVAR was more popular as the first therapeutic strategy in patients undergoing AAA treatment in Iran; consequently, we assumed that 80% of elective surgical operations were performed via EVAR. Although by comparison with OSR, the EVAR procedure has a favorable hospital course, its superiority has never been proven and its long-term efficacy has been challenged recently [54, 55]. The result of a systematic review and meta-analysis conducted by Bulder et al [54] showed that the 30-day mortality rate for EVAR was lower than that with OSR (1.16 vs 3.27%), but the long-term survival rates were similar for EVAR and OSR (hazard ratio: 1.01, 1.00, and 0.98 for 3, 5, and 10 years, respectively). In another systematic review study, Chen et al [55] found that OSR and EVAR had similar all-cause mortality over a 5-year follow-up, which was maintained after at least 10 years of follow-up. The authors also reported that a significantly lower proportion of their patients undergoing open repair required re-intervention (odds ratio: 0.38, 95% confidence interval: 0.24 to 0.64), which was maintained
over 5 years of follow-up. Based on our estimations, the mean cost of EVAR was about twice the mean cost of OSR in Iran. Therefore, since OSR is comparable with EVAR at least in terms of long-term efficacy, it is possible to boost the likelihood of the cost-effectiveness of AAA screening by using OSR in lieu of EVAR.

**Limitation**

In this study, to investigate the cost-effectiveness of AAA screening in Iran, we used a Markov model, the validity of which was confirmed in previous studies [26, 34, 35]. However, given the scarcity of information regarding the prevalence of AAA in Iran and the resultant uncertainty about some parameters of the model, we utilized deterministic and probabilistic sensitivity analyses to assess the impact of parameter uncertainty.

**Conclusion**

In conclusion, our results showed that at a willingness-to-pay of 1 GDP per capita ($5628) per QALY gained, a 1-time AAA screening program for men aged 65 years or above could not be cost-effective; whereas at a willingness-to-pay of twice the GDP per capita per QALY gained, the AAA screening program could be cost-effective in Iran. In addition, AAA screening in high-risk groups could be cost-effective at a willingness-to-pay of 1 GDP per capita per QALY gained.

**Declarations**

**Ethics approval and consent to participate:** The study has been approved by Rajaie Cardiovascular and Medical and Research Center (RHC). The present study is cost-effective analysis and consequently, obtaining informed consent was not applicable.

**Consent for publication:** The present study has been approved by RHC for publication

**Availability of data and materials.** The data and materials of the present study are available

**Competing interests:** None

**Funding:** None

**Authors’ contributions**

RD, PS, MZ, Majid Maleki have devised the project and the main conceptual ideas. YB, JS, OS, JM, PF AND Majid Moeini have worked on data collection. RD and YB performed the data analysis. RD and PS have written the manuscript. MZ, Majid Maleki, JS, OS and JM review the manuscript.

**Acknowledgements:** None

**References**

1. Alcorn, H.G., et al., *Risk factors for abdominal aortic aneurysms in older adults enrolled in The Cardiovascular Health Study*. Arteriosclerosis, thrombosis, and vascular biology, 1996. **16**(8): p. 963-970.
2. Ali, Z., et al., *Perioperative myocardial injury after elective open abdominal aortic aneurysm repair predicts outcome*. European Journal of Vascular and Endovascular Surgery, 2008. **35**(4): p. 413-419.

3. Badger, S.A., et al., *Advantages and pitfalls of abdominal aortic aneurysm screening in high-risk patients*. Vascular, 2008. **16**(4): p. 201-206.

4. Badger, S.A., et al., *Risk factors for abdominal aortic aneurysm and the influence of social deprivation*. Angiology, 2008. **59**(5): p. 559-566.

5. Ballard, D.J., et al., *Surgery for small asymptomatic abdominal aortic aneurysms*. The Cochrane Library, 2008.

6. Bengtsson, H., et al., *A population based screening of abdominal aortic aneurysms (AAA)*. European journal of vascular surgery, 1991. **5**(1): p. 53-57.

7. Collin, J., B. Heather, and J. Walton, *Growth rates of subclinical abdominal aortic aneurysms—implications for review and rescreening programmes*. European journal of vascular surgery, 1991. **5**(2): p. 141-144.

8. Conway, A., et al., *First-year results of a national abdominal aortic aneurysm screening programme in a single centre*. British Journal of Surgery, 2012. **99**(1): p. 73-77.

9. Bartoli, M.A., et al., *Secondary procedures after infrarenal abdominal aortic aneurysms endovascular repair with second-generation endografts*. Annals of vascular surgery, 2012. **26**(2): p. 166-174.

10. Hobbs, S., et al., *Strategies to improve the effectiveness of abdominal aortic aneurysm screening programmes*. Journal of medical screening, 2004. **11**(2): p. 93-96.

11. Kasper, D., et al., *Harrison's principles of internal medicine*. 2015: McGraw-Hill Professional Publishing.

12. Coughlin, P., et al., *Meta-analysis of prospective trials determining the short-and mid-term effect of elective open and endovascular repair of abdominal aortic aneurysms on quality of life*. British Journal of Surgery, 2013. **100**(4): p. 448-455.

13. Prinssen, M., et al., *A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms*. New England Journal of Medicine, 2004. **351**(16): p. 1607-1618.

14. Lederle, F.A., et al., *Long-term comparison of endovascular and open repair of abdominal aortic aneurysm*. New England Journal of Medicine, 2012. **367**(21): p. 1988-1997.

15. Participants, E.T., *Endovascular Aneurysm Repair Versus Open Repair in Patients With Abdominal Aortic Aneurysm (EVAR Trial 1): Randomized Controlled Trial*. ACC Current Journal Review, 2005. **14**(10): p. 52-53.

16. De Bruin, J.L., et al., *Long-term outcome of open or endovascular repair of abdominal aortic aneurysm*. New England Journal of Medicine, 2010. **362**(20): p. 1881-1889.

17. Khaira, H., L. Herbert, and M. Crowson, *Screening for abdominal aortic aneurysms does not increase psychological morbidity*. Annals of the Royal College of Surgeons of England, 1998. **80**(5): p. 341.
18. Kim, L., et al., Screening for abdominal aortic aneurysms: the effects of age and social deprivation on screening uptake, prevalence and attendance at follow-up in the MASS trial. Journal of Medical Screening, 2004. 11(1): p. 50-53.

19. Earnshaw, J., et al., Screening for abdominal aortic aneurysms in men. BMJ: British Medical Journal, 2004. 328(7448): p. 1122.

20. Scott, R. and M.A.S.S. Group, The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. The Lancet, 2002. 360(9345): p. 1531-1539.

21. Lindholt, J.S., et al., Screening for abdominal aortic aneurysms: single centre randomised controlled trial. Bmj, 2005. 330(7494): p. 750.

22. Norman, P.E., et al., Population based randomised controlled trial on impact of screening on mortality from abdominal aortic aneurysm. Bmj, 2004. 329(7477): p. 1259.

23. Wanhainen, A., et al., Cost-effectiveness of different screening strategies for abdominal aortic aneurysm. Journal of vascular surgery, 2005. 41(5): p. 741-751.

24. Silverstein, M.D., et al. Abdominal aortic aneurysm (AAA): cost-effectiveness of screening, surveillance of intermediate-sized AAA, and management of symptomatic AAA. in Baylor University Medical Center Proceedings. 2005. Taylor & Francis.

25. Henriksson, M. and F. Lundgren, Decision-analytical model with lifetime estimation of costs and health outcomes for one-time screening for abdominal aortic aneurysm in 65-year-old men. British Journal of Surgery: Incorporating European Journal of Surgery and Swiss Surgery, 2005. 92(8): p. 976-983.

26. Kim, L., et al., How cost-effective is screening for abdominal aortic aneurysms? Journal of Medical Screening, 2007. 14(1): p. 46-52.

27. Mani, K., et al., Screening for abdominal aortic aneurysm among patients referred to the vascular laboratory is cost-effective. European Journal of Vascular and Endovascular Surgery, 2010. 39(2): p. 208-216.

28. Moll, F.L., et al., Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. European journal of vascular and endovascular surgery, 2011. 41: p. S1-S58.

29. LeFevre, M.L., Screening for abdominal aortic aneurysm: US Preventive Services Task Force recommendation statement. Annals of internal medicine, 2014. 161(4): p. 281-290.

30. Stather, P., et al., International variations in AAA screening. European Journal of Vascular and Endovascular Surgery, 2013. 45(3): p. 231-234.

31. Sampson, U.K., et al., Estimation of global and regional incidence and prevalence of abdominal aortic aneurysms 1990 to 2010. Global heart, 2014. 9(1): p. 159-170.
32. Salem, M., et al., *Should Asian men be included in abdominal aortic aneurysm screening programmes?* European Journal of Vascular and Endovascular Surgery, 2009. **38**(6): p. 748-749.

33. Li, X., et al., *Prevalence and trends of the abdominal aortic aneurysms epidemic in general population-a meta-analysis.* PloS one, 2013. **8**(12).

34. Glover, M., et al., *Cost-effectiveness of the National Health Service abdominal aortic aneurysm screening programme in England.* British Journal of Surgery, 2014. **101**(8): p. 976-982.

35. Zarrouk, M., et al., *Cost-effectiveness of screening for abdominal aortic aneurysm in combination with medical intervention in patients with small aneurysms.* European Journal of Vascular and Endovascular Surgery, 2016. **51**(6): p. 766-773.

36. Nordon, I.M., et al., *Pathophysiology and epidemiology of abdominal aortic aneurysms.* Nature reviews cardiology, 2011. **8**(2): p. 92.

37. Mirsharifi, R., et al., *The prevalence of abdominal aortic aneurysm in Iranian male population over 65 years old.* Tehran University Medical Journal, 2011. **69**(5).

38. Munoz-Mendoza, J., et al., *Trends in abdominal aortic aneurysm prevalence and mortality in non-European countries.* International journal of cardiology, 2013. **170**(2): p. e38-e40.

39. Thompson, S., et al., *Systematic review and meta-analysis of the growth and rupture rates of small abdominal aortic aneurysms: implications for surveillance intervals and their cost-effectiveness.* Health Technology Assessment (Winchester, England), 2013. **17**(41): p. 1-118.

40. Zeinali, A.M.H., et al., *Endovascular aortic aneurysm and dissection repair (EVAR) in Iran: descriptive midterm follow-up results.* Iranian Journal of Radiology, 2016. **13**(1).

41. Anvari, M.S., et al., *Ascending aorta aneurysm and blood group A among Iranian patients.* Thrombosis research, 2013. **131**(2): p. e51-e53.

42. Spronk, S., et al., *Cost-effectiveness of screening for abdominal aortic aneurysm in the Netherlands and Norway.* British Journal of Surgery, 2011. **98**(11): p. 1546-1555.

43. Lederle, F.A., et al., *Outcomes following endovascular vs open repair of abdominal aortic aneurysm: a randomized trial.* Jama, 2009. **302**(14): p. 1535-1542.

44. Organization, W.H., *Global Health Observatory (GHO) data: Country statistics.* Pridobljeno s [http://www.who.int/gho/countries/en](http://www.who.int/gho/countries/en), 2018.

45. Official exchange rate (LCU per US$), p.a., URL: [https://data.worldbank.org/indicator/PA.NUS.FCRF](https://data.worldbank.org/indicator/PA.NUS.FCRF). 2017, CD.

46. Earnshaw, J., *The National Health Service Abdominal Aortic Aneurysm Screening Programme in England.* Gefässchirurgie, 2014. **19**(6): p. 528-533.
47. Svensjö, S., et al., Screening for abdominal aortic aneurysm in 65-year-old men remains cost-effective with contemporary epidemiology and management. European Journal of Vascular and Endovascular Surgery, 2014. 47(4): p. 357-365.

48. Reile, R., et al., The Cost-Effectiveness of Abdominal Aortic Aneurysm Screening in Estonia. Value in health regional issues, 2020. 22: p. 1-6.

49. Roshanali, F., et al., Abdominal aorta screening during transthoracic echocardiography. Echocardiography, 2007. 24(7): p. 685-688.

50. Shirani, S., et al., Ultrasonographic screening for abdominal aortic aneurysms in Iranian candidates for coronary artery bypass graft surgery. Archives of Iranian medicine, 2009. 12(4): p. 383-388.

51. Anjum, A. and J. Powell, Is the incidence of abdominal aortic aneurysm declining in the 21st century? Mortality and hospital admissions for England & Wales and Scotland. European Journal of Vascular and Endovascular Surgery, 2012. 43(2): p. 161-166.

52. Guirguis-Blake, J.M., et al., Primary care screening for abdominal aortic aneurysm: updated evidence report and systematic review for the US Preventive Services Task Force. Jama, 2019. 322(22): p. 2219-2238.

53. Owens, D.K., et al., Screening for Abdominal Aortic Aneurysm: US Preventive Services Task Force Recommendation Statement. Jama, 2019. 322(22): p. 2211-2218.

54. Bulder, R., et al., Meta-analysis of long-term survival after elective endovascular or open repair of abdominal aortic aneurysm. British Journal of Surgery, 2019. 106(5): p. 523-533.

55. Chen, Z.-g., et al., The long-term outcomes of open and endovascular repair for abdominal aortic aneurysm: a meta-analysis. Asian journal of surgery, 2019.

**Tables**

**Table 1:** Parameters used in the Markov model to evaluate screening for AAA
| Variable                                           | Point Estimate(range) | Distribution | Source |
|----------------------------------------------------|-----------------------|--------------|--------|
| Prevalence of AAA                                  | 0.03 (0.01- 0.04)     | beta         | [36-38]|
| Proportion of small AAAs                           | 0.789                 | Dirichlet    | [34]   |
| Proportion of medium AAAs                          | 0.12                  | Dirichlet    | [34]   |
| Proportion of large AAAs                           | 0.091                 | Dirichlet    | [34]   |
| **Transition Probabilities (3-monthly)**           |                       |              |        |
| From no AAA to small AAA                           | 0.00207 (0.0013- 0.0029) | gamma       | [34]   |
| From small AAA to medium AAA                       | 0.037 (0.033- 0.042)  | beta         | [39]   |
| From medium AAA to large AAA                       | 0.175 (0.119- 0.231)  | beta         | [39]   |
| **Probability of Rupture (3-monthly)**             |                       |              |        |
| In small AAA                                       | 0.00023 (0.00013- 0.00038) | beta       | [39]   |
| In medium AAA                                       | 0.00160 (0.00043- 0.00588) | beta       | [39]   |
| In undetected large AAA                            | 0.0282 (0.01974- 0.03666) | beta       | [34]   |
| In detected large AAA                               | 0.0125 (0.008- 0.018) | beta         | [34]   |
| In detected large AAA contraindicated for surgery   | 0.0282 (0.01974- 0.03666) | beta       | [34]   |
| Probability of opportunistic detection             | 0.0114 (0.00798- 0.01482) | beta       | [34]   |
| Probability of emergency surgery after rupture     | 0.368 (0.200- 0.500)  | beta         | [34]   |
| Probability of elective surgery if large AAA       | 0.918 (0.85- 0.95)    | beta         | [35]   |
| Probability of reoperation after EVAR (year 1-2)   | 0.063 (0.0441- 0.0819) | beta       | [35]   |
| Probability of reoperation after OSR (year 1)      | 0.039 (0.0273- 0.0507) | beta       | [35]   |
| Proportion of patients undergoing screening (%)     | 0.75 (0.65- 0.85)     | beta         | expert opinion |
| Proportion of EVAR as emergency surgery (%)         | 0.05 (0- 0.1)         | beta         | expert opinion |
| Proportion of EVAR as elective surgery (%)          | 0.8 (0.7- 0.9)        | beta         | expert opinion |
| **Death After**                                     |                       |              |        |
| Elective EVAR                                       | 0.013 (0.004- 0.023)  | beta         | [35, 40, 42] |
| Elective OSR                                        | 0.030 (0.021- 0.050)  | beta         | [34, 42] |
| Emergency EVAR                                      | 0.307 (0.152- 0.492)  | beta         | [35, 42] |
|                      |                  |         |           |
|----------------------|------------------|---------|-----------|
| Emergency OSR        | 0.5 (0.35-0.65)  | beta    | [41]      |
| **Health-Related Quality of life (EQ-5D index)** |                  |         |           |
| 65-69 years old      | 0.83             | NA [35] |           |
| 70-74 years old      | 0.81             | NA [35] |           |
| 75-79 years old      | 0.79             | NA [35] |           |
| 80+ years old        | 0.74             | NA [35] |           |
| **Health-Related Disutilities (EQ-5D index)** |                  |         |           |
| Post EVAR and OSR    | -0.02            | NA [43] |           |
| All-cause mortality  | age-specific      | NA [44] |           |
| Discount rate (%)    | 3 (0-6)          | NA      | expert opinion |
| **Cost of**          |                  |         |           |
| EVAR (per patient) (US$) | 12433 (8289-20722) | gamma | our estimation |
| OSR (per patient) (US$) | 6442 (4295-10737)  | gamma | our estimation |
| Screening test (ultrasound) per patient (US$) | 39.17 (25.25-57.29) | normal | our estimation |
| Small AAA follow-up (per cycle) (US$) | 9.79 (6.31-14.32) | normal | our estimation |
| Medium AAA follow-up (per cycle) (US$) | 19.58 (12.63-28.64) | normal | our estimation |

*Mortality rates related to AAA repair were defined as those that occurred within 30 days after surgery.

NA, Not applicable; AAA, Abdominal aortic aneurysm; EVAR, Endovascular aneurysm repair; OSR, Open surgical repair
Table 2: Incremental cost-effectiveness ratio of an abdominal aortic aneurysm screening strategy compared with no screening

| Strategy     | Average  | Incremental  | ICER          |
|--------------|----------|--------------|---------------|
|              | Cost(US$) | QALY | LYG | Cost(US$) | QALY | LYG | Cost(US$) per QALY | Cost(US$) per LYG |
| No screening | 267       | 8.780 | 10.890 | - | - | - | - | - | - |
| Screening    | 407       | 8.806 | 10.924 | 140 | 0.025 | 0.034 | 5566 | 4106 |

QALY, Quality-adjusted life-year; LYG, Life-years gained; ICER, Incremental cost-effectiveness ratio
Table 3. Result of the 1-way sensitivity analysis of the selected variables

| Variable                                                                 | Cost (s)                  | QALY                      | ICER ($ per QALY) |
|--------------------------------------------------------------------------|---------------------------|---------------------------|-------------------|
|                                                                          | No screening | Screening | Increment | No screening | Screening | Increment |
| Discount rate (%)                                                       |              |           |           |              |           |           |
| 0                                                                        | 364          | 512       | 148       | 11.005       | 11.040    | 0.036     | 4,151   |
| 0.6                                                                     | 199          | 332       | 133       | 7.182        | 7.200     | 0.018     | 7,334   |
| Cost of EVAR($)                                                         |              |           |           |              |           |           |
| 8,289                                                                   | 203          | 308       | 104       | 8.780        | 8.806     | 0.025     | 4,144   |
| 20,722                                                                  | 393          | 604       | 212       | 8.780        | 8.806     | 0.025     | 8,409   |
| Probability of the rupture in undetected large AAAs (3-monthly)          |              |           |           |              |           |           |
| 0.0197                                                                  | 267          | 406       | 139       | 8.799        | 8.817     | 0.018     | 7,524   |
| 0.0367                                                                  | 266          | 406       | 141       | 8.765        | 8.796     | 0.031     | 4,618   |
| Cost of the screening test (ultrasound) per patient($)                   |              |           |           |              |           |           |
| 25                                                                      | 267          | 396       | 130       | 8.780        | 8.806     | 0.025     | 5,153   |
| 57                                                                      | 267          | 420       | 154       | 8.780        | 8.806     | 0.025     | 6,103   |
| Prevalence of AAA (%)                                                   |              |           |           |              |           |           |
| 0.01                                                                    | 235          | 338       | 103       | 8.795        | 8.812     | 0.017     | 7,890   |
| 0.04                                                                    | 298          | 475       | 177       | 8.766        | 8.799     | 0.034     | 5,275   |
| Probability of death after emergency OSR                                 |              |           |           |              |           |           |
| 0.35                                                                    | 267          | 407       | 140       | 8.786        | 8.809     | 0.023     | 5,984   |
| 0.65                                                                    | 266          | 406       | 140       | 8.775        | 8.802     | 0.027     | 5,203   |
| Probability of emergency surgery after rupture                           |              |           |           |              |           |           |
| 0.2                                                                     | 241          | 387       | 147       | 8.771        | 8.800     | 0.028     | 5,233   |
| 0.5                                                                     | 287          | 422       | 135       | 8.787        | 8.810     | 0.023     | 5,886   |
| Proportion of EVAR as elective surgery (%)                               |              |           |           |              |           |           |
| 0.7                                                                     | 255          | 388       | 133       | 8.780        | 8.805     | 0.025     | 5,311   |
| 0.9                                                                     | 278          | 425       | 147       | 8.781        | 8.806     | 0.025     | 5,818   |
| Transition probabilities from medium AAA to large AAA (3-monthly)        |              |           |           |              |           |           |
| 0.119                                                                   | 257          | 391       | 135       | 8.788        | 8.811     | 0.023     | 5,833   |
| 0.231                                                                   | 271          | 414       | 143       | 8.776        | 8.802     | 0.026     | 5,419   |
AAA, Abdominal aortic aneurysm; EVAR, Endovascular aneurysm repair; OSR, Open surgical repair

Figures

Figure 1
Figure 2